Compounds and methods for treating seizure disorders
This invention provides methods for alleviating paroxysmal disorders in an animal, particularly epilepsy, by modulating glycolysis in brain cells.
1. A method for treating epilepsy, in an adult or juvenile human, the method comprising the step of administering to the human an effective amount of 2-deoxyglucose (2-DG).
2. The method of claim 1 for treating an epileptic seizure.
3. The method of claim 2 , wherein 2-DG is administered prior to the human having an epileptic seizure.
4. The method of claim 2 , wherein 2-DG is administered to the human during an epileptic seizure.
5. The method of claim 2 , wherein 2-DG is administered to the human after the human has an epileptic seizure.
6. The method of claim 2 , wherein 2-DG is administered within 30 minutes before or 24 hours after the human has an epileptic seizure.
7. A method for reducing or inhibiting epileptic seizures in an adult or juvenile human, the method comprising the step of administering to the human an effective amount of 2-DG.
8. The method of claim 7 , wherein 2-DG is administered prior to the human having an epileptic seizure.
9. The method of claim 7 , wherein 2-DG is administered to the human during an epileptic seizure.
10. The method of claim 7 , wherein 2-DG is administered to the human after the human has an epileptic seizure.
11. The method of claim 7 , wherein 2-DG is administered within 30 minutes before or 24 hours after the human has an epileptic seizure.
12. A method for raising the seizure threshold in brain or neural tissue of a human in need thereof, the method comprising the step of administering to the human having epilepsy an effective amount of 2-DG.
13. The method of claim 12 wherein the brain or neural tissue comprise adult or juvenile brain or neural tissue.
14. The method of claim 12 , wherein 2-DG is administered prior to the human having an epileptic seizure.
15. The method of claim 12 , wherein 2-DG is administered the human having an epileptic seizure.
16. The method of claim 12 , wherein 2-DG is administered to the human after the human has an epileptic seizure.
17. The method of claim 12 , wherein 2-DG is administered within 30 minutes before or 24 hours after the human has an epileptic seizure.
18. A method for reducing epileptic bursting in human brain cells in a human, the method comprising the step of contacting the cells with an effective amount of 2-DG.
19. The method of claim 18 wherein the human brain cells are adult or juvenile brain cells.
20. The method of claims 18 , wherein epileptic bursting is associated with the human animal having an epileptic seizure.
21. The method of claim 20 , wherein 2-DG is administered prior to the human having an epileptic seizure.
22. The method of claim 20 , wherein 2-DG is administered prior to the human having an epileptic seizure.
23. The method of claim 20 , wherein 2-DG is administered to the human after the human has an epileptic seizure.
24. The method of claim 20 , wherein 2-DG is administered within 30 minutes before or 24 hours after the human has an epileptic seizure.
25. The method of claim 20 wherein the brain cells are adult or juvenile brain cells.
26. A method of treating epilepsy in a human in need thereof by administering to said human an effective amount of 2-deoxyglucose (2-DG).
27. The method of claim 26 , wherein 2-DG is administered to the human within minutes of the onset of epileptic symptoms in the human.
28. The method of claim 26 , wherein 2-DG is administered to the human before the onset of epileptic symptoms in the human.